Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C

被引：88

作者：

Terui, Y ^{[1
]}

Saito, T

Watanabe, H

Togashi, H

Kawata, S

Kamada, Y

Sakuta, S

机构：

[1] Yamagata Univ, Sch Med, Dept Internal Med 2, Yamagata, Japan

[2] Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Osaka, Japan

来源：

HEPATOLOGY | 2002年 / 36卷 / 04期

关键词：

D O I：

10.1053/jhep.2002.32679

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1022 / 1022

页数：1

共 10 条

[1] Angiotensin II induces contraction and proliferation of human hepatic stellate cells [J].

Bataller, R ;

Ginès, P ;

Nicolás, JM ;

Görbig, MN ;

Garcia-Ramallo, E ;

Gasull, X ;

Bosch, J ;

Arroyo, V ;

Rodés, J .

GASTROENTEROLOGY, 2000, 118 (06) :1149-1156

[2]

BONKOVSKY HL, 1997, HEPATOLOGY S1, V26, P143

[3] THE N-TERMINAL PROPEPTIDE OF COLLAGEN TYPE-III IN SERUM REFLECTS ACTIVITY AND DEGREE OF FIBROSIS IN PATIENTS WITH CHRONIC LIVER-DISEASE [J].

FREI, A ;

ZIMMERMANN, A ;

WEIGAND, K .

HEPATOLOGY, 1984, 4 (05) :830-834

[4] Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis [J].

González-Abraldes, J ;

Albillos, A ;

Bañares, R ;

Del Arbol, LR ;

Moitinho, E ;

Rodríguez, C ;

González, M ;

Escorsell, A ;

García-Pagán, JC ;

Bosch, J .

GASTROENTEROLOGY, 2001, 121 (02) :382-388

[5] Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension [J].

Schepke, M ;

Werner, E ;

Biecker, E ;

Schiedermaier, P ;

Heller, J ;

Neef, M ;

Stoffel-Wagner, B ;

Hofer, U ;

Caselmann, WH ;

Sauerbruch, T .

GASTROENTEROLOGY, 2001, 121 (02) :389-395

[6] Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis [J].

Schneider, AW ;

Kalk, JF ;

Klein, CP .

HEPATOLOGY, 1999, 29 (02) :334-339

[7] Interleukin 10: The magic bullet for liver fibrosis? [J].

Schuppan, D ;

Hahn, EG .

GASTROENTEROLOGY, 2000, 119 (05) :1412-1413

[8] A MULTICENTER RANDOMIZED CONTROLLED DOSE STUDY OF URSODEOXYCHOLIC ACID FOR CHRONIC HEPATITIS-C [J].

TAKANO, S ;

ITO, Y ;

YOKOSUKA, O ;

OHTO, M ;

UCHIUMI, K ;

HIROTA, K ;

OMATA, M .

HEPATOLOGY, 1994, 20 (03) :558-564

[9] Reduced plasma transforming growth factor-β1 levels in patients with chronic hepatitis C after interferon-α therapy:: association with regression of hepatic fibrosis [J].

Tsushima, H ;

Kawata, S ;

Tamura, S ;

Ito, N ;

Shirai, Y ;

Kiso, S ;

Doi, Y ;

Yamada, A ;

Oshikawa, O ;

Matsuzawa, Y .

JOURNAL OF HEPATOLOGY, 1999, 30 (01) :1-7

[10] Angiotensin-II type I receptor interaction is a major regulator for liver fibrosis development in rats [J].

Yoshiji, H ;

Kuriyama, S ;

Yoshii, J ;

Ikenaka, Y ;

Noguchi, R ;

Nakatani, T ;

Tsujinoue, H ;

Fukui, H .

HEPATOLOGY, 2001, 34 (04) :745-750

← 1 →